Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Wolfe starts Merck at Peer Perform, notes competitive overhangs
Wolfe Research initiated coverage of Merck (MRK) with a Peer Perform rating. The firm said the main sentiment driver for Merck is ...
Hosted on MSN20h
Merck KGaA Earnings Growth Beats Expectations
After-tax profit was 812 million euros compared with 740 million in the same period last year, Merck said Thursday. The ...
MarketWatch7d
Merck & Co. Inc. stock rises Thursday, still underperforms market
Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...
bovnews1d
Merck & Co Inc (MRK) Stock: Understanding Its Underlying Value
On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...
Yale Daily News1d
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Reuters22h
Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...
bovnews4d
The Merck & Co Inc Stock Thriller: Decoding the Mystery Behind MRK’s Recent Movements
Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...